LivaNova PLC LIVN

Morningstar Rating
$82.98 +0.42 (0.51%)
View Full Chart

Company Report

LivaNova Has Found New Opportunities for Innovation in Its Strongholds

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

Price vs Fair Value

LIVN is trading at a LOCK|>yfzr$ premium.
Price
$82.56
Fair Value
^&
Uncertainty
LOCK|mN>
1-Star Price
LOCK|s.L%
5-Star Price
LOCK|.X%
Economic Moat
LOCK|zhDw^
Capital Allocation
LOCK|PxG

Bulls Say, Bears Say

Bulls

LivaNova continues to enjoy a large footprint in the heart-lung machine market, which comes with the sale of consumable oxygenators.

Bears

We think LivaNova has less bandwidth or infrastructure than larger competitors to integrate and optimize innovation following the acquisition of new technology.

News

Trading Information

Previous Close Price
$82.56
Day Range
$82.4583.80
52-Week Range
$41.0285.27
Bid/Ask
$77.50 / $85.40
Shares Outstanding
54.93M
Market Cap
$4.56B
Volume/Avg
465,972 / 794,825

Key Statistics

Price/Earnings (Normalized)
20.63
Price/Sales
3.16
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
3,300

Competitors

Valuation

Metric
LIVN
MDT
EW
Price/Earnings (Normalized)
20.6315.3334.15
Price/Book Value
3.742.175.15
Price/Sales
3.162.978.54
Price/Cash Flow
16.6712.3434.64
Price/Earnings
LIVN
MDT
EW

Financial Strength

Metric
LIVN
MDT
EW
Quick Ratio
1.061.363.30
Current Ratio
1.332.134.42
Interest Coverage
3.519.58
Quick Ratio
LIVN
MDT
EW

Profitability

Metric
LIVN
MDT
EW
Return on Assets (Normalized)
8.67%7.76%11.79%
Return on Equity (Normalized)
19.31%14.65%15.28%
Return on Invested Capital (Normalized)
14.98%9.93%13.18%
Return on Assets
LIVN
MDT
EW

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|r%q@q@#LOCK|<<t>$164B
Stryker Corp
SYK
LOCK|Ss&Nh&q&LOCK|#V%$126B
Medtronic PLC
MDT
LOCK|%#N#%VqLOCK|BpJ@$107B
Boston Scientific Corp
BSX
LOCK|MxX^xHmLOCK|cLXg$67B
Edwards Lifesciences Corp
EW
LOCK|Ct!J?$#LOCK|Z$D&$53B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|k@V%nP@LOCK|$j$29B
DexCom Inc
DXCM
LOCK|$@N<&&fQLOCK|L@<!$29B
Koninklijke Philips NV ADR
PHG
LOCK|R@rLOCK|bJ$27B
Steris PLC
STE
LOCK|Q<^f#vLLOCK|%J#k$21B
Zimmer Biomet Holdings Inc
ZBH
LOCK|QM!!Jj$LOCK|X&&$18B

Sponsor Center